Markets:

Overview

News

Currencies

International

Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

4.420 -0.030 (-0.67%)

Streaming Delayed Price Updated: 10:47 AM EDT, Mar 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict ↗

March 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome

March 29, 2022

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

March 25, 2022

Taysha Gene Therapies (NASDAQ:TSHA) will host a conference call at 08:00 AM ET on March 31, 2022, to discuss Q4 2021 earnings results. How to Attend Taysha Gene Therapies (TSHA)...

Via Benzinga

Taysha Reports Efficacy, Safety Data From High Dose Cohort For Neurological Disorder Gene Therapy Trial ↗

January 31, 2022

Taysha Gene Therapies Inc (NASDAQ: TSHA) has

Via Benzinga

Taysha Gene Plans Protocol Amendment After Patient Death In Gene Therapy Trial ↗

January 27, 2022

Taysha Gene Therapies Inc (NASDAQ: TSHA) reported

Via Benzinga

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗

March 27, 2022

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

Via Benzinga

Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31

March 24, 2022

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences

March 23, 2022

From Taysha Gene Therapies, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2022 ↗

March 09, 2022

Upgrades Roth Capital upgraded the previous rating for Hudson Technologies Inc (NASDAQ:HDSN) from Neutral to Buy. For the fourth quarter, Hudson Technologies had an EPS of $0.13,...

Via Benzinga

Two Insider Moonshots Rising on Sudden Buying ↗

February 10, 2022

Biotech insiders are among the most important investors to pay close attention to. Here are two that show good signs for the future.

Via InvestorPlace

Stocks That Hit 52-Week Lows On Tuesday ↗

March 15, 2022

During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

March 14, 2022

On Monday, 671 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows: Alibaba Group Holding (NYSE:BABA) was the largest firm by...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

March 08, 2022

Tuesday's session saw 729 companies set new 52-week lows. Areas of Interest About Today's 52-Week Lows: Amazon.com (NASDAQ:AMZN) was the largest firm on a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 ↗

March 01, 2022

Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...

Via Benzinga

Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium

February 09, 2022

From Taysha Gene Therapies, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

February 22, 2022

During Tuesday's trading, 505 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The company with the largest market cap to...

Via Benzinga

Executives Buy Around $62M Of 3 Stocks ↗

February 07, 2022

The Nasdaq index jumped more than 200 points on Friday after Amazon.com, Inc. (NASDAQ: AMZN) reported better-than-expected earnings for its fourth quarter.

Via Benzinga

Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy

January 31, 2022

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of β-Hexosaminidase A Enzyme Activity in Patients With GM2 Gangliosidosis

January 27, 2022

From Taysha Gene Therapies, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 20, 2022

Gainers TCR2 Therapeutics (NASDAQ:TCRR) s...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

January 19, 2022

During Wednesday's morning trading, 400 companies set new 52-week lows. 52-Week Low Highlights: Intuitive Surgical (NASDAQ:ISRG) was the largest company by...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

January 06, 2022

On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this...

Via Benzinga

Taysha Gene Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 06, 2022

From Taysha Gene Therapies, Inc.

Via Business Wire

Stocks Hitting New 52-Week Lows Today ↗

January 03, 2022

On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was...

Via Benzinga

Taysha Gene Therapies to Participate in Panel Discussions at the LifeSci Partners 11th Annual Corporate Access Event

January 03, 2022

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High Dose Cohort and Long-Term Clinical Data for TSHA-120 in Giant Axonal Neuropathy

December 28, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus ↗

December 26, 2021

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts, and COVID-19 treatment and vaccine developments dictating sentiment. Here are the key...

Via Talk Markets

The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year ↗

December 26, 2021

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating...

Via Benzinga

Taysha Gene Therapies Added to the ICE Biotechnology Index

December 23, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies Announces Positive Preliminary Clinical Safety Data For First-Generation Construct In CLN7 Disease and Completion of Next-Generation CLN7 Construct Design

December 22, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.